Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144-Reference-Cited by-同舟云学术

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

Published:2012-07 Issue:7 Volume:12 Page:531-537
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Robb Merlin L,Rerks-Ngarm Supachai,Nitayaphan Sorachai,Pitisuttithum Punnee,Kaewkungwal Jaranit,Kunasol Prayura,Khamboonruang Chirasak,Thongcharoen Prasert,Morgan Patricia,Benenson Michael,Paris Robert M,Chiu Joseph,Adams Elizabeth,Francis Donald,Gurunathan Sanjay,Tartaglia Jim,Gilbert Peter,Stablein Don,Michael Nelson L,Kim Jerome H

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference26 articles.

1. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand;Rerks-Ngarm;N Engl J Med,2009

2. Vaccines: correlates of vaccine-induced immunity;Plotkin;Clin Infect Dis,2008

3. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys;Letvin;Sci Transl Med,2011

4. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge;Reynolds;J Virol,2010

5. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160;Lee;J Infect Dis,2004

Cited by 194 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study;eBioMedicine;2024-10

2. Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1;Virology;2024-09

3. A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2;Antiviral Research;2024-05

4. A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1;eLife;2024-04-15

5. A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1;eLife;2024-04-15